Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 401–500 of 1,000
Veve, M. P., Mercuro, N. J., Sangiovanni, R. J., Santarossa, M., & Patel, N. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac297 · Cited by 36
Garey, K. W., Jo, J., Gonzales-Luna, A. J., Lapin, B. R., Deshpande, A., Wang, E., Hasson, B. R., Pham, S. V., Huang, S. P., Reese, P. R., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53570 · Cited by 34
Self-citationButyrate Protects against Clostridium difficile Infection by Regulating Bile Acid Metabolism
Wang, S., Xiang, L., Li, F., Deng, W., Lv, P., & Chen, Y. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04479-22 · Cited by 39
“Despite aggressive medical and surgical interventions, current medical technology remains challenging due to the high mortality rate of patients with severe CDI (17, 18).”
BackgroundGonzales-Luna, A. J., Carlson, T. J., Dotson, K. M., Poblete, K., da Costa, G. A. P. C., Miranda, J. M., Lancaster, C. K., Walk, S. T., Tupy, S., Begum, K., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1721335 · Cited by 30
“ease severity as classified by the Infectious Diseases Society of America (IDSA) guidelines published in 2017 [3].”
MethodSelf-citationOlesen, S. W., & Gerardin, Y. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa170 · Cited by 32
Antibiotics Associated With Clostridium difficile Infection
Rafey, A., Jahan, S., Farooq, U., Akhtar, F., Irshad, M., Nizamuddin, S., & Parveen, A. (2023) · Cureus · doi:10.7759/cureus.39029 · Cited by 30
“We evaluated patients regarding antibiotics given for at least four days [15] in the last three months and features of severe infection or not [19].”
MethodBanz, A., Lantz, A., Riou, B., Foussadier, A., Miller, M. A., Davies, K., & Wilcox, M. H. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00452-18 · Cited by 30
“lines strongly recommend a two-stage testing approach (8, 10).”
BackgroundSelf-citationMiller, R., Morillas, J. A., Brizendine, K. D., & Fraser, T. G. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01764-19 · Cited by 30
“This underscores the importance of individual patient assessment, particularly since it has been shown that the cause of diarrhea in hospitalized patients, even those with leukocytosis or hematologic malignancy, is most often not CDI (5).”
BackgroundMethodInfluentialLin, K., Zahlanie, Y., Ortwine, J. K., Mang, N. S., Wei, W., Brown, L. S., & Prokesch, B. C. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa182 · Cited by 29
“difficile infections as a method of preventing these infections [15, 16].”
MethodRecurrent Clostridioides difficile infection: Recognition, management, prevention
Tsigrelis, C. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87gr.20001 · Cited by 35
Roshan, N., Clancy, A. K., & Borody, T. J. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00339-w · Cited by 32
Enoch, D., Murray‐Thomas, T., Adomakoh, N., Dedman, D., Georgopali, A., Francis, N. A., & Karas, A. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.09.025 · Cited by 33
Lee, J. D., Heintz, B. H., Mosher, H. J., Livorsi, D. J., Egge, J. A., & Lund, B. C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1902 · Cited by 30
Boyce, J. M. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.04.003 · Cited by 53
Wexler, A. G., Guiberson, E. R., Beavers, W. N., Shupe, J. A., Washington, M. K., Lacy, D. B., Caprioli, R. M., Spraggins, J. M., & Skaar, E. P. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109683 · Cited by 33
Kucharzik, T. F., Dignass, A. U., Atreya, R. N., Bokemeyer, B., Esters, P., Herrlinger, K. R., Kannengießer, K., Kienle, P., Langhorst, J., Lügering, A., et al. (2023) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2060-0935 · Cited by 42
Cho, S., Spencer, E. A., Hirten, R. P., Grinspan, A. M., & Dubinsky, M. C. (2019) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002172 · Cited by 32
Allegretti, J. R., Kao, D. H., Phelps, E. L., Roach, B., Smith, J. D., Ganapini, V., Kassam, Z., Xu, H., & Fischer, M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5450-4 · Cited by 30
“There has been some benefit to once daily dosing of vancomycin during a course of systemic antibiotics to prevent CDI recurrence in high-risk patients, but the risk of further diminishing the microbiome with additional antibiotics has not been assessed [8].”
Gut microbiome-based strategies for host health and disease
Wang, C., Bai, J., Chen, X., Song, J., Zhang, Y., Wang, H., & Suo, H. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2176464 · Cited by 29
“In particular, it can quickly restore the bacterial flora structure destroyed by antibiotics, and inhibit C. difficile infections, and thus has been approved as a standard therapy in clinical guidelines for the diagnosis and treatment of recurrent C. difficile infections (McDonald et al. 2018).”
BackgroundRise of the guardians: Gut microbial maneuvers in bacterial infections
Gupta, U., & Dey, P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121993 · Cited by 33
Salamonowicz, M., Ociepa, T., Frączkiewicz, J., Szmydki‐Baran, A., Matysiak, M. J., Czyźewski, K., Wysocki, M. S., Gałązka, P., Zalas‐Więcek, P., Irga‐Jaworska, N., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3316-5 · Cited by 29
“Recent clinical studies demonstrated bezlotoxumab (anti-CD toxin B monoclonal antibodies) to be a valuable therapeutic option [37, 38].”
Legenza, L. M., Barnett, S. G., Rose, W. E., Bianchini, M. L., Safdar, N., & Coetzee, R. (2018) · BMJ Global Health · doi:10.1136/bmjgh-2018-000889 · Cited by 29
Hecker, M. T., Son, A. H., Murphy, N. N., Sethi, A. K., Wilson, B. M., Watkins, R., & Donskey, C. J. (2019) · American Journal of Infection Control · doi:10.1016/j.ajic.2019.01.026 · Cited by 30
Carlson, T. J., Endres, B. T., Pham, J. L., Gonzales-Luna, A. J., Alnezary, F. S., Nebo, K., Miranda, J. M., Lancaster, C. K., Bassères, E., Begum, K., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz552 · Cited by 31
Self-citationFinding the relevance of antimicrobial stewardship for cystic fibrosis
Cogen, J. D., Kahl, B. C., Maples, H. D., McColley, S. A., Roberts, J. A., Winthrop, K. L., Morris, A. M., Holmes, A. H., Flume, P. A., VanDevanter, D. R., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.02.012 · Cited by 29
Alagna, L., Palomba, E., Mangioni, D., Bozzi, G., Lombardi, A., Ungaro, R., Castelli, V., Prati, D., Vecchi, M. L., Muscatello, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165619 · Cited by 35
“Specifically, FMT is now considered a recommended therapeutic option for patients with multiple recurrences of CDI, when appropriate antibiotic treatments have failed, as per the latest guidelines of the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) [66].”
MethodRomyasamit, C., Thatrimontrichai, A., Aroonkesorn, A., Chanket, W., Ingviya, N., Saengsuwan, P., & Singkhamanan, K. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.572633 · Cited by 31
Escudero-Sánchez, R., Ruiz‐Ruigómez, M., Fradejas, J. F., Fernández, S. G., Olmedo, M., Yuste, A. C., Alijo, Á. V., Díaz‐Pollán, B., Hernández, M. R., Merino, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010002 · Cited by 29
Binary Toxin Expression by Clostridioides difficile Is Associated With Worse Disease
Young, M. K., Leslie, J. L., Madden, G. R., Lyerly, D. M., Carman, R. J., Lyerly, M. W., Stewart, D. B., Abhyankar, M. M., & Petri, W. A. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac001 · Cited by 29
Phothichaisri, W., Chankhamhaengdecha, S., Janvilisri, T., Nuadthaisong, J., Phetruen, T., Fagan, R. P., & Chanarat, S. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02361-21 · Cited by 34
Boeriu, A. M., Roman, A., Fofiu, C., & Dobru, D. E. (2022) · Pathogens · doi:10.3390/pathogens11070819 · Cited by 31
Protein target highlights in CASP15 : Analysis of models by structure providers
Alexander, L. T., Durairaj, J., Kryshtafovych, A., Abriata, L. A., Bayo, Y., Bhabha, G., Breyton, C., Caulton, S. G., Chen, J., Degroux, S., et al. (2023) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.26545 · Cited by 29
Seekatz, A. M., Wolfrum, E., DeWald, C. M., Putler, R. K. B., Vendrov, K. C., Rao, K. K., & Young, V. B. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.05.017 · Cited by 33
Yin, J., Kociolek, L. K., Same, R. G., Hsu, A. J., Amoah, J., & Tamma, P. D. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz492 · Cited by 29
Antimicrobial resistance in Clostridium difficile ribotype 017
Imwattana, K., Knight, D. R., Kullin, B., Collins, D. A., Putsathit, P., Kiratisin, P., & Riley, T. V. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1701436 · Cited by 29
“inferior to that of vancomycin, the current standard treatment [77], and the future of cadazolid use in the treatment of CDI is now uncertain [78].”
BackgroundRisk Factors Associated with Recurrent Clostridioides difficile Infection
Negruţ, N., BUNGAU, S. G., Behl, T., Khan, S. A., Vesa, C. M., Bustea, C., Nistor-Cseppento, C. D., Rus, M., Pavel, F. M., & Ţiţ, D. M. (2020) · Healthcare · doi:10.3390/healthcare8030352 · Cited by 35
“International treatment guidelines for CDI recommend vancomycin or fidaxomicin as first-line drugs rather than Metronidazole [20].”
BackgroundDoll, M. E., Marra, A. R., Apisarnthanarak, A., Al-Maani, A. S., Abbas, S. M., & Rosenthal, V. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.039 · Cited by 35
Aby, E. S., Vaughn, B. P., Enns, E. A., & Rajasingham, R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac207 · Cited by 28
Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan
Wu, K.-S., Syue, L.-S., Cheng, A., Yen, T., Chen, H.-M., Chiu, Y.-H., Hsu, Y., Chiu, C.-H., Su, T.-Y., Tsai, W.-L., et al. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.02.002 · Cited by 30
Updated Management Guidelines for Clostridioides difficile in Paediatrics
Gnocchi, M., Gagliardi, M., Gismondi, P., Gaiani, F., Angelis, G. L. D., & Esposito, S. (2020) · Pathogens · doi:10.3390/pathogens9040291 · Cited by 34
Oh, S. J., Shin, G. Y., Soh, H., Lee, J. G., Im, J. P., Eun, C. S., Lee, K., Park, D. I., Han, D. S., Kim, H. J., et al. (2020) · Intestinal Research · doi:10.5217/ir.2020.00039 · Cited by 30
“difficile via stool toxin assay, PCR or toxigenic culture in stool specimens, in accordance with international guidelines.(19) Disease activity was assessed according to the Mayo score(20) and disease extent was categorized according to the Montreal classification.”
MethodStephenson, B., Lanzas, C., Lenhart, S., Lazcano-Ponce, E. C., Bintz, J., Dubberke, E. R., & Day, J. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05501-w · Cited by 35
Self-citationAl‐Bakri, A. G., Akour, A. A., & Al‐Delaimy, W. K. (2021) · BMC Medical Ethics · doi:10.1186/s12910-021-00587-6 · Cited by 30
Żebrowska-Różańska, P., Łaczmańska, I., & Łaczmański, Ł. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.630052 · Cited by 36
Wu, X., Shen, W., Deshpande, A., Olaitan, A. O., Palmer, K. L., Garey, K. W., & Hurdle, J. G. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00585-21 · Cited by 29
“not recommend metronidazole as a first-line monotherapy for adult CDI but still recommends intravenous metronidazole in combination with oral vancomycin for severe CDI (6).”
BackgroundInfluentialSelf-citationHow to: prophylactic interventions for prevention of Clostridioides difficile infection
Reigadas, E., van Prehn, J., Falcone, M., Fitzpatrick, F., Vehreschild, M. J. G. T., Kuijper, E. J., & Bouza, E. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.037 · Cited by 31
Alonso, C. D., Kelly, C. P., Garey, K. W., Gonzales-Luna, A. J., Williams, D. N., Daugherty, K., Cuddemi, C., Villafuerte-Gálvez, J., White, N. C., Chen, X., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab826 · Cited by 34
Self-citationJan, N., Hays, R. A., Oakland, D. N., Kumar, P., Ramakrishnan, G., Behm, B. W., Petri, W. A., & Marie, C. S. (2021) · mSphere · doi:10.1128/msphere.00669-21 · Cited by 28
“otics such as vancomycin or fidaxomicin (1).”
Beran, A., Sharma, S., Ghazaleh, S., Lee‐Smith, W., Aziz, M., Kamal, F., Acharya, A., & Adler, D. G. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001667 · Cited by 30
Donnell, M. M. O., Hegarty, J. W., Healy, B., Schulz, S., Walsh, C. J., Hill, C., Ross, R. P., Rea, M. C., Farquhar, R., & Chesnel, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-13248-4 · Cited by 30
Bainum, T. B., Reveles, K. R., Hall, R. G., Cornell, K., & Álvarez, C. A. (2023) · Microorganisms · doi:10.3390/microorganisms11020387 · Cited by 33
“Both the 2017 IDSA and 2021 ACG guidelines make the distinction between non-severe and severe CDI based on the patient’s white blood count and serum creatinine [8,10].”
BackgroundHost Immunity and Immunization Strategies for Clostridioides difficile Infection
Naz, F., & Petri, W. A. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00157-22 · Cited by 28
Dehlholm-Lambertsen, E., Hall, B. K., Baunwall, S. M. D., Jørgensen, C. W., Jensen, M. E., Larsen, S., Jensen, J. S., Ehlers, L. H., Dahlerup, J. F., & Hvas, C. L. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819843002 · Cited by 30
Musuuza, J., Hundt, A. S., Carayon, P., Christensen, K., Ngam, C. R., Haun, N., & Safdar, N. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.150 · Cited by 27
Kelly, C. R., Fischer, M., Grinspan, A. M., & Allegretti, J. R. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.06.034 · Cited by 29
Self-citationLuo, Y., Lucas, A. L., & Grinspan, A. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05821-1 · Cited by 26
Recent Trends of Infectious Complications Following Heart Transplantation
Multani, A., Moayedi, Y., Puing, A. G., Henricksen, E. J., Garvert, D. W., Gómez, C. A., Tremblay‐Gravel, M., Bunce, P. E., Luikart, H. I., Ross, H. J., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003307 · Cited by 27
“This is especially true for Clostridioides difficile, where PCR-based detection cannot discriminate between the asymptomatic carrier state and active infection.(11) Some of the patients deemed to have UTI may have had asymptomatic bacteriuria, treatment of which is no longer recommended in heart transplant recipients.”
BackgroundWolf in Sheep’s Clothing: Clostridioides difficile Biofilm as a Reservoir for Recurrent Infections
Meza‐Torres, J., Auria, E., Dupuy, B., & Tremblay, Y. D. N. (2021) · Microorganisms · doi:10.3390/microorganisms9091922 · Cited by 31
Fecal Microbial Transplantation in Critically Ill Patients—Structured Review and Perspectives
Cibulková, I., Řehořová, V., Hajer, J., & Duška, F. (2021) · Biomolecules · doi:10.3390/biom11101459 · Cited by 30
Johnson, T. M., Molina, K. C., Howard, A. H., Schwarz, K. A., Allen, L., Huang, M., Bajrovic, V., & Miller, M. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab674 · Cited by 27
Clostridioides difficile infection in Africa: A narrative review
Kullin, B., Abratt, V. R., Reid, S. J., & Riley, T. V. (2022) · Anaerobe · doi:10.1016/j.anaerobe.2022.102549 · Cited by 27
Hayes, J. F. (2022) · Antibiotics · doi:10.3390/antibiotics11050644 · Cited by 38
“Reduction in antibiotic use and stringent infection prevention policy have significant benefits towards preventing this infection [7].”
BackgroundDong, N., Li, Z., Qin, P., Qiang, C., Yang, J., Niu, Y., Niu, X. R., Liu, X., Wang, W. G., Wen, B., et al. (2022) · Journal of Hospital Infection · doi:10.1016/j.jhin.2022.09.004 · Cited by 33
Yang, Z., Qin, J., Zhao, L., Chen, T., Huang, Q., Jian, Y., Zhao, Q., Yang, S., Li, Q., Liu, Q., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.046 · Cited by 28
Abenavoli, L., Scarpellini, E., Paravati, M. R., Scarlata, G. G. M., Boccuto, L., Tilocca, B., Roncada, P., & Luzza, F. (2023) · Nutrients · doi:10.3390/nu15163569 · Cited by 31
Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients
Abu‐Sbeih, H., Ali, F. S., & Wang, Y. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0677-6 · Cited by 29
Kelly, C. P., Poxton, I. R., Shen, J., Wilcox, M. H., Gerding, D. N., Zhao, X., Laterza, O., Railkar, R. A., Güriş, D., & Dorr, M. B. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz809 · Cited by 28
Self-citationAntonelli, M. M., Martín‐Loeches, I., Dimοpoulos, G., Gasbarrini, A., & Vallecoccia, M. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05873-x · Cited by 30
Fachi, J. L., Pral, L. P., de Assis, H. C., de Oliveira, S., Rodovalho, V. D. R., dos Santos, J. A. C., Fernandes, M. F., Matheus, V. A., Sesti‐Costa, R., Basso, P. J., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2023.2297872 · Cited by 32
“97 In contrast, HBO is a well-established modality used in treating chronic non-healing wounds and certain type of infections.”
BackgroundSuárez-Bode, L., Barrón, R., Pérez, J. L., & Mena, A. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.12.002 · Cited by 31
Ridinilazole: a novel antimicrobial for Clostridium difficile infection
Cho, J. C. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0336 · Cited by 27
Dionne, J. C., Sullivan, K., Mbuagbaw, L. C. E., Takaoka, A., Duan, E. H., Alhazzani, W. A., Devlin, J. W., Duprey, M. S., Moayyedi, P., Armstrong, D., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028237 · Cited by 28
“difficile infection will be adjudicated using the Infectious Disease Society of America criteria.(19) For all possible cases, the following will also be adjudicated: stool frequency, complications (eg, colectomy), treatments (antibiotics, surgery) and overall severity according to guidelines of the European Society of…”
MethodGlycopeptide Hypersensitivity and Adverse Reactions
Huang, V., Clayton, N. A., & Welker, K. (2020) · Pharmacy · doi:10.3390/pharmacy8020070 · Cited by 32
Dieterle, M. G., Putler, R. K. B., Perry, D. A., Menon, A., Close, L. A., Perlman, N., Penkevich, A., Standke, A. K., Keidan, M., Vendrov, K. C., et al. (2020) · mBio · doi:10.1128/mbio.00180-20 · Cited by 26
Severe Clostridium difficile infections in intensive care units: Diverse clinical presentations
Lee, J., Hung, Y., Tsai, B., Tsai, P.-J., & Ko, W. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.07.012 · Cited by 26
Garey, K. W., Begum, K., Lancaster, C. K., Gonzales-Luna, A. J., Bui, D., Mercier, J., Yue, C. S., Ducharme, M. P., Hu, M., Vince, B. D., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa364 · Cited by 26
Self-citationMicrobiome-based interventions: therapeutic strategies in cancer immunotherapy
Chervin, C. S., & Gajewski, T. F. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.11.001 · Cited by 29
Allegretti, J. R., Nije, C., McClure, E. L., Redd, W. D., Wong, D., Zhou, J., Bazarbashi, A. N., McCarty, T. R., Hathorn, K., Shen, L., et al. (2021) · JGH Open · doi:10.1002/jgh3.12497 · Cited by 26
Popa, D., Neamtu, B. M., Mihalache, M., Boicean, A., Banciu, A., Banciu, D. D., Moga, D. F. C., & Bîrluțiu, V. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245822 · Cited by 32
“Currently, the FMT is included in the European CDI treatment guidelines for multiple recurrences [16], mild or severe rCDI, and refractory CDI [17], while in the American CDI treatment guidelines, after the second or subsequent rCDI [18].”
BackgroundMethodInfluentialConover, K. R., Absah, I., Ballal, S. A., Brumbaugh, D. E., Cho, S., Cardenas, M. C., Knackstedt, E. D., Goyal, A., Jensen, M. K., Kaplan, J. L., et al. (2023) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003714 · Cited by 32
Vázquez‐Cuesta, S., Villar-Gómara, L., Lozano-García, N., Fernández, A. I., Olmedo, M., Alcalá, L., Marín, M., Muñóz, P., Bouza, E., & Reigadas, E. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1130701 · Cited by 30
Infecciosas, I. D. I. S. G. M. S. D. M. C. Y. E., Bouza, E., Aguado, J. M., Alcalá, L., Almirante, B., Alonso‐Fernández, P., Borges-Sa, M., Cobo, J., Guardiola, J., Horcajada, J. P., et al. (2020) · Revista Española de Quimioterapia · doi:10.37201/req/2065.2020 · Cited by 33
Characterization of the human gut virome in metabolic and autoimmune diseases
Fujimoto, K., Miyaoka, D., & Uematsu, S. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00218-6 · Cited by 31
Ziegler, M. J., Landsburg, D. J., Pegues, D. A., Bilker, W. B., Gilmar, C., Kucharczuk, C., Gorman, T., Bink, K., Moore, A., Fitzpatrick, R., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.11.023 · Cited by 26
Tarr, G. A. M., Chui, L., Lee, B. E., Pang, X.-L., Ali, S., Nettel‐Aguirre, A., Vanderkooi, O. G., Berenger, B. M., Dickinson, J. A., Tarr, P. I., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1021 · Cited by 28
Imaging of Gastrointestinal Tract Perforation
Shin, D., Rahimi, H., Haroon, S. A., Merritt, A., Vemula, A., Noronha, A. M., & LeBedis, C. A. (2019) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2019.08.004 · Cited by 25
Oludiran, A., Courson, D. S., Stuart, M. D., Radwan, A. R., Poutsma, J. C., Cotten, M. L., & Purcell, E. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215289 · Cited by 22
Dunn, A. N., Radakovich, N., Ancker, J. S., Donskey, C. J., & Deshpande, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa152 · Cited by 27
Boekhoud, I. M., Michel, A., Corver, J., Jahn, D., & Smits, W. K. (2020) · mSphere · doi:10.1128/msphere.00728-20 · Cited by 25
Tariq, R., Laguio-Vila, M. R., Tahir, M. W., Orenstein, R., Pardi, D. S., & Khanna, S. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284821994046 · Cited by 25
Tixier, E. N., Verheyen, E., Luo, Y., Grinspan, L. T., Du, C., Ungaro, R. C., Walsh, S., & Grinspan, A. M. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06908-4 · Cited by 32
Nicholson, M. R., Alexander, E., Ballal, S. A., Davidovics, Z. H., Docktor, M., Dole, M., Gisser, J. M., Goyal, A., Hourigan, S. K., Jensen, M. K., et al. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab202 · Cited by 30
Hogan, C. A., Hitchcock, M. M., Frost, S., Kapphahn, K., Holubar, M. K., Tompkins, L. S., & Banaei, N. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.02187-21 · Cited by 25
Edwards, P. T., Thurm, C. W., Hall, M., Busing, J. D., Kahn, S. A., Kellermayer, R., Kociolek, L. K., Oliva‐Hemker, M. M., Sammons, J. S., Weatherly, M., et al. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.08.030 · Cited by 29
Garey, K. W., Dubberke, E. R., Guo, A. X., Harvey, A., Yang, M., García-Horton, V., Fillbrunn, M. K., Wang, H., Tillotson, G., Bancke, L. L., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad383 · Cited by 25
Self-citationFecal Microbiota Transplantation: Information for the Pediatrician
Oliva‐Hemker, M. M., Kahn, S. A., Steinbach, W. J., SECTION ON GASTROENTEROLOY, H., Cohen, M. B., Brumbaugh, D. E., Cole, C. R., Dotson, J. L., Harpavat, S., Lightdale, J. R., et al. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062922 · Cited by 30
Walker, A. M., Timbrook, T. T., Hommel, B., & Prinzi, A. M. (2024) · Diagnostics · doi:10.3390/diagnostics14070752 · Cited by 27
Lam, S. W., Neuner, E. A., Fraser, T. G., Delgado, D., & Chalfin, D. B. (2018) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2018.139 · Cited by 25
Abughanimeh, O. K. M., Qasrawi, A. H., Kaddourah, O., Momani, L. A. A., & Ghanimeh, M. A. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1533673 · Cited by 27
“In general, treatment depends on disease severity and is similar to that of the general population [40].”
BackgroundMethodInfluentialAppaneal, H. J., Caffrey, A. R., Beganovic, M., Avramovic, S., & LaPlante, K. L. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz032 · Cited by 25
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.